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Phosphotidylinositol (PtdIns) signaling is tightly regulated, both spatially and temporally, by 
subcellularly localized PtdIns kinases and phosphatases that dynamically alter downstream 
signaling events 1. Joubert Syndrome (JS) characterized by a specific midbrain-hindbrain 
malformation (“molar tooth sign”) and variably associated retinal dystrophy, nephronophthisis, 
liver fibrosis and polydactyly 2, and is included in the newly emerging group of “ciliopathies”. In 
patients linking to JBTS1, we identified mutations in the INPP5E gene, encoding inositol 
polyphosphate-5-phosphatase E, which hydrolyzes the 5-phosphate of PtdIns(3,4,5)P3 and 
PtdIns(4,5)P2. Mutations clustered in the phosphatase domain and impaired 5-phosphatase 
activity, resulting in altered cellular PtdIns ratios. INPP5E localized to cilia in major organs 
affected in JS, and mutations promoted premature destabilization of cilia in response to 
stimulation. Thus, these data links PtdIns signaling to the primary cilium, a cellular structure that 
is becoming increasingly appreciated for its role in mediating cell signals and neuronal function.
Joubert syndrome locus 1 (JBTS1, MIM%213300) was mapped to the distal q-arm of 
chromosome 9, between D9S1826-D9S1838 3, in two JS Emirate families variably 
associated with retinopathy, and a proven “molar tooth” sign (MTI-007 and MTI-008 
previously called Family A and C, respectively, Fig. 1a, Supplemental Table 1) 3. To refine 
the candidate interval, we recruited two additional unaffected MTI-007 and two affected 
MTI-008 family members, and performed a 5K SNP analysis, confirming JBTS1 in 
MTI-007 (Supplemental Fig. 1). Family MTI-008 produced a linkage peak at JBTS1, among 
several other peaks of similar amplitude, with a maximum LOD score of about +1.94. As a 
result, these SNP scans failed to significantly narrow the candidate interval (Supplemental 
Table 2).
An additional 25 consanguineous families with JS were analyzed, and three (MTI-134, 
MTI-610, and MTI-627, of Emirate, Turkish and Egyptian descent) showed at least one 
peak that overlapped with JBTS1. Two Italian families (COR-10 and COR-21) also linked to 
JBTS1 4. Haplotype analysis suggested that MTI-007 and MTI-134 were identical-by-
descent, as were COR-10 and COR-21 (data not shown). Together these analyses defined a 
candidate interval of 3.5 MB in distal 9q34.2-tel, containing approximately 86 annotated 
candidate genes (Supplemental Table 3), 57 of which were screened for sequence changes, 
whereas the remaining 29 either lacked an open reading frame or were excluded due to lack 
of developmental expression. This extensive screening identified the INPP5E gene as 
mutated in each JBTS1-linked family (Fig. 1a-b).
The INPP5E mutations were notable for two reasons. First, all identified mutations were 
amino acid transversions that clustered within the enzymatically-active phosphatase domain 
(Fig. 1b). Second, each altered the charge of highly basic evolutionarily conserved amino 
acid residues (Fig. 1c), together suggesting that these mutations might alter enzymatic 
activity. None of these mutations were encountered among 188 control chromosomes from 
healthy ethnically matched individuals, and all segregated with the disease in each family. 
We modeled these mutations using the published crystal structure of synaptojanin5, the only 
inositol 5-phosphatase for which structural data is available. We found that each of the 
altered residues (with one exception, R563) was predicted to project its charged tail toward 
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the presumed binding pocket of the PtdIns substrate (Supplemental Fig. 2), suggesting that 
these mutations might alter substrate specificity.
To test the effects of INPP5E mutations on PtdIns phosphatase activity, we 
immunoprecipated tagged wildtype and enzymatically null (D477N 6), together with each 
mutation separately from mammalian cells (resulting in similar protein levels, Supplemental 
Fig. 3) and then analyzed phosphatase activity against PtdIns(3,4,5)P3 and PtdIns(4,5)P2, 
the presumed cellular INPP5E substrates (Fig. 2a). We found that each of the JBTS1 
missense mutations severely disrupted phosphatase activity towards PtdIns(3,4,5)P3 (Fig. 
2b, p < 0.05 activity for each mutant, N = 3 independent experiments). Of note, since the 
R512W/R515W variants were observed on a single haplotype, we reasoned that probably 
only one was driving the defect in enzymatic activity, and under separate analysis, the 
R515W mutation was shown to be the major contributor to the defective enzymatic activity 
(data not shown). Comparison with phosphatase activity using PtdIns(4,5)P2 as substrate 
showed similar although not as severely compromised results as compared with wildtype 
(Fig. 2c), suggesting that PtdIns(3,4,5)P3 may be the relevant substrate in JBTS1. Because 
overexpression of INPP5E was previously shown to block Akt phosphorylation in response 
to PDGF stimulation in cultured cells (presumably by depleting levels of PtdIns(3,4,5)P3 
and PtdIns(4,5)P2) 7, we next tested the effect of overexpression of each of the patient 
mutations in this published assay. Not only did patient mutations fail to block Akt signaling, 
but elevated basal levels of pAkt were also apparent in unstimulated cells (Supplemental 
Fig. 4). We conclude that the JBTS1-associated missense mutations impair phosphatase 
activity towards putative PtdIns substrates, which can alter downstream signaling events.
Next, we tested whether the absence of endogenous catalytic INPP5E activity results in an 
altered PtdIns profiles in cells. Although difficult to measure absolute levels PtdIns moieties 
in cells, the model predicted an increased ratio of PtdIns(4,5)P2/PtdIns(4)P due to a block in 
this enzymatic step (Fig. 2a), and thus skin fibroblasts from MTI-610 patient 1 and 2 
(brother and sister) were assessed for PtdIns(4,5)P2/PtdIns(4)P ratio. In control unstimulated 
growth-arrested fibroblasts we found a PtdIns(4,5)P2/PtdIns(4)P ratio of about 0.63, 
whereas in both patient fibroblast samples the ratio was increased by about 20% (p = 0.05, N 
= 3 independent experiments, Fig. 2c). We found no differences in expression levels of 
INPP5E in this or other patient fibroblast samples with INPP5E mutations (Supplemental 
Fig. 5). We conclude that catalytic activity of INPP5E is required for maintenance of 
homeostatic ratios of PtdIns in cells.
In order to investigate a possible connection with ciliopathies, we examined INPP5E 
localization in cells with well-described cilia. The RPE-hTERT line (immortalized retinal 
pigment epithelia) display a primary cilia in >80% of growth-arrested cells 8,9. 
Coimmunostaining with pericentrin, a marker of the pericentriolar matrix, showed INPP5E 
immediately adjacent to the base of the cilium (Fig. 3a). This was confirmed by INPP5E 
coimmunostaining with acetylated tubulin, a marker of the ciliary axoneme, as well as with 
ARL13B, a cilia marker 10-12, which showed tight-colocalization of INPP5E to the ciliary 
axoneme, with only minimal INPP5E localized to non-ciliary locations (Fig. 3b). 
Transfection of wild-type GFP-tagged INPP5E into IMCD-3 cells under ciliary-permissive 
conditions demonstrated ciliary localization (Supplemental Fig. 6), and we found no defect 
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in ciliary localization of any of the JBTS1-associated patient missense mutations when 
expressed in these cells (data not shown). By contrast, cells at mitotic stages (after cilium 
withdrawal) showed cytoplasmic localization (Supplemental Fig. 7). The data suggests that 
INPP5E localizes predominantly to the primary cilium during interphase in the cell lines 
tested.
We stained for INPP5E in organs affected in JS from the GFP-Centrin2 transgenic mouse 
(marks the base of the cilium) 13, and identified cilia localization in each. In renal collecting 
tubules, cilia were evident projecting from the epithelium into the lumen. In this mouse, 
many cells were marked by luminal localization of the pair of centrioles, and from this site, 
the majority of cells had an INPP5E-positive cilium projecting into the lumen (Fig. 3c). In 
the developing cerebellum, cilia have been identified on a population of neuroblasts in the 
cerebellar internal granule layer 14. We identified these ciliated cells based upon GFP signal 
at the centrioles, and identified INPP5E-positive cilia projecting into the parenchyma in the 
vast majority of these cells (Fig. 3d), and similar ciliary localization was observed in the 
hepatic bile ducts (not shown). We also observed that INPP5E localized to the region 
adjacent to the basal body and connecting cilium in retinal photoreceptor cells (Fig. 3e-f). 
Therefore, INPP5E is predominantly localized adjacent to or within the cilium in each of the 
major organs affected in JS.
To assess the potential function of INPP5E at the primary cilium, we utilized primary 
fibroblasts from patient MTI-610-V-1. These cells displayed essentially normal growth 
characteristics, as well as percentage of ciliated cells compared with controls (81% vs. 76%, 
p > 0.05, Fig. 4a), suggesting that INPP5E enzymatic activity is not required for ciliogenesis 
or cilia maintenance, at least not in fibroblasts. However, the cilium is not a fixed structure, 
and is labile to the application of serum-derived factors such as PDGF 15. Since serum is a 
potent activator of the PtdIns pathway in cultured cells, we predicted that the altered PtdIns 
profile might render cilia in mutant cells more labile to the application of serum. We applied 
serum to control and MTI-610-V-1 cells and scored the percentage of cells retaining a 
cilium, based upon acetylated-tubulin and ARL13B staining at specific time intervals. By 4 
hr after serum application, wild-type cells had an 8% cilia withdrawal rate whereas INPP5E 
mutant cells had a 33% cilia withdrawal rate, (73% vs. 43%, p < 0.01, N = 3 independent 
experiments). At the 8 hr and 24 hr timepoints, the percentage of cells with visible cilia had 
equalized to about 40% in the two genotypes, suggesting that INPP5E controls timing of 
cilia disassembly during early response to serum.
To determine if the reduced number of ciliated mutant cells is due to an enhanced rate of 
cilia withdrawal in the absence of functional INPP5E, we performed scanning electron 
microscopy. Prior to the addition of serum, we found that the length of the primary cilium 
was approximately the same in control vs. MTI-610-V-1 serum-starved fibroblasts, 
measuring ~3 um in length (Fig. 4b-e). At the 4 hr timepoint (where we saw the maximal 
difference in cilia number), however, cilium length of the MTI-610 fibroblasts was about 
half of control. These data were quantified in x-y sections from cells with remaining visible 
cilia as evidenced by immunostaining for ARL13B prior to, and then at 4 hr and 8 hr after 
serum addition. We found a significant decrease in average cilia length at 4 hr after serum 
stimulation in mutant vs. controls (2.73 vs. 1.28 um, wildtype vs. MTI-610, p < 0.01, n > 30 
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cells for each condition), whereas no difference was apparent either before serum or after 8 
hrs (Supplemental Fig. 8). Thus ciliary disassembly is more rapid in the absence of full 
INPP5E activity compared with wildtype.
Following ascertainment of fibroblast samples from additional patients with INPP5E 
mutations, we noted some alterations in cell proliferation rates in culture, and thus tested 
quiescent cells for ability to reenter the cell cycle. While MTI-610 fibroblasts had no 
apparent alteration in cell cycle reentry (based upon Ki67 staining or BrdU incorporation), 
MTI-134 and MTI-627 exhibited a reduction in the percentage of mitotically active cells 
following serum addition (Supplemental Fig. 9). As MTI-134 and MTI-627 had more severe 
reduction in enzymatic activity than MTI-610 in the in vitro assay (0% and 8.5% vs.15%, 
presented in Fig. 2), the data suggests that residual but not full function of INPP5E may be 
required for this serum-based cell-cycle reentry. MTI-610 fibroblasts exhibited a normal 
percentage of mitotically active cells, however, a greater percentage of these mitotically 
synchronized cells reentered the cell cycle initially (Ki67 staining between 18-24hrs) and 
progressed through the cell cycle more rapidly (reduction of BduU incorporation from 24hrs 
to 30hrs) than control fibroblasts, suggesting that INPP5E enzymatic activity may also 
influence the rate of cell cycle progression. Not all serum-based responses are abnormal in 
these patient samples, however. For instance, there were no alterations in low-dose serum-
dependent scratch-wound assay healing (Supplemental Fig. 10), which we designed to be 
migration-dependent but largely proliferation-independent 16. We conclude that INPP5E 
may play specific serum-dependent cellular roles, mediating both ciliary stability as well as 
cell cycle dynamics.
Our data demonstrates that hypomorphic mutations in INPP5E lead to JS, providing the first 
evidence of a link between PtdIns signaling and the ciliopathies. It will be important to 
determine if the developmental defects observed in JS are the result of defects in cilia 
maintenance or due to a more broadly defined disruption in PtdIns signaling. Since PDGFαα 
receptor has been localized to primary cilia 17, and since PDGF is one of the key serum-
derived factors that mediates cilia withdrawal concurrent with cell cycle reentry 18 it is 
possible that PDGF and other factors that utilize cilia as signaling centers have downstream 
pathways that are regulated through specific localization and function of INPP5E.
Previous studies have hinted at possible connections between PtdIns signaling and the 
cilium. Tubby mutant mice have cilia-like phenotypes and the protein encoded from the 
mutant gene binds specific PtdIns including PtdIns3,4,5(P3) 19. Furthermore, Bardet-Biedl 
syndrome shares similar ciliopathy features to JS, and the BBS5 protein can bind PtdIns 9. 
However, our findings are the first, to our knowledge, to directly implicate defective 
enzymatic conversion within the PtdIns class. The fact that INPP5E displays enrichment 
within the ciliary axoneme makes it tempting to speculate that PtdIns signaling may not just 
function to regulate cilia stability, but also that this signaling may occur within the cilium. 
An alternative model is that INPP5E might be sequestered within the cilium, but exert its 
activity within the cytoplasm, similar to the models being proposed for Sonic hedgehog 
signaling 20. The identification of a key regulatory enzyme in this process highlights an 
important area of research with clinical relevance.
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Twenty-seven consanguineous families from the Middle East, Turkey and Europe were 
included in this study based upon the following criteria: 1) at least one individual with a 
neuroradiographically proven “molar tooth sign” associated with any JS or related disorder 
phenotype; 2) evidence for linkage to the JBTS1 locus; 3) exclusion of linkage to any other 
of the known JBTS loci (JBTS2-9). Whenever possible, patients underwent a full diagnostic 
protocol as previously reported 21. Brain MRI analysis was completed during the clinical 
assessment using standard sequence protocols. Parental written informed consent was 
obtained from all families, and the study was approved by the HRPP Committees of UCSD 
(La Jolla) and CSS-Mendel Institute (Rome).
Genome-wide screen and fine mapping of the JBTS1 locus
A 5K whole genome linkage scan was performed in all informative families using the 
Illumina Linkage IVb mapping panel 22, and analyzed with easyLINKAGE-Plus software 
23, which runs Allegro version 1.2c in a PC Windows interface to calculate multipoint LOD 
scores. Parameters were set to autosomal recessive with full penetrance, and disease allele 
frequency of 0.001. Fine mapping on selected individuals was performed with the 
Affymetrix 250K Nsp1 SNP array and results analyzed using pedigree-free identity-by-
descent mapping. Short tandem repeat polymorphic markers at the JBTS1 locus were used as 
previously published 4.
Mutation screening
Mutations were screened using a combination of single stranded conformational 
polymorphism analysis and direct sequencing as described 24,25.
Bioinformatics
Protein evolutionary conservation was determined by aligning amino acids from the Human 
Genome Browser (http://www.genome.ucsc.edu). Ciliary proteome was searched using web-
based tools 26,27. Protein folding and intermolecular interactions were predicted using 
Swiss-Model with crystallized PtdIns 5-phosphatase domain of synaptojanin bound to 
Ca(2+) and PtdIns(1,4)P2 5. The resulting INPP5E structure was manipulated with PyMOL 
software by importing amino acid sequence for wildtype and mutant and comparing the 
likely docking site for PtdIns.
Biochemical assays
INPP5E cDNA 7 was cloned in frame with EGFP into pcDNA3.0 for expression. Patient 
mutations were individually engineered into the INPP5E cDNA in a Myc-tagged vector, 
stably transfected into 293T cells using the T-Rex tetracycline-regulated system 
(Invitogen)7, immunoprecipitated using Myc-tag, confirmed by Western to each express 
comparable amounts (Supplemental Fig. 3), and then used in a modified PtdIns(4,5)P2 
hydrolysis assay as described 28. PtdIns(3,4,5)P3 hydrolysis was measured by adding 
purified substrate to the immunoprecipitates at 37°C for 10 min, followed by malachite 
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green for an additional 10 min 29. Released inorganic phosphate was measured at 650 nm, 
compared against a standard curve, and performed in triplicate. Assessment of 
PtdIns(4,5)P2/PtdIns(4)P ratio from patient primary cells were metabolically labeled and 
performed as described 30. Stably transfected 293T cells were stimulated with 50ng/ml of 
PDGF and analyzed for Akt signaling as described7.
Histology
Mouse tissues from wildtype or GFP-CETN2 mice were immunostained with an affinity 
purified peptide-specific INPP5E rabbit antisera that reacts with human and mouse as 
reported 31 at 1:200 and images acquired on a DeltaVision imaging system with 5-10 cycles 
of deconvolution.
Fibroblasts assay
Primary skin fibroblasts from patient and unaffected passage-matched control were grown at 
similar confluence for 3 days in the absence of serum. Ciliary disassembly and wound 
healing was assessed as described 18,32. Cell-cycle re-entry was interrogated as described 
33 with 20% serum addition to sub-confluent fibroblasts. BrdU (10 uM) was applied for 1 
hr, and antigens detected with antibodies to Ki67(1:1000) and BrdU (1:1500) (Abcam # 
ab66155 and ab6326).
Scanning Electron microscopy
Fibroblasts were fixed in 2.5% glutaraldehyde/0.1 M cacodylate buffer (CB) (pH 7.4) for 30 
min at 25C, rinsed (0.1 M CB), postfixed (1% OsO4/0.1 M CB) for 30 min at 4C, 
dehydrated with a graded alcohol series, which was displaced with hexamethyldisilazane, 
and evaporated overnight before sputter coating samples with palladium and imaged on 
XL30 ESEM-FEG.
Cilia length quantification
Cilia length was correlated in the x-y-z vs. x-y using the Volocity rendering software. 3D 
reconstruction of cilia using DeltaVision imaging system with 100X objective with 0.1 um 
z-steps allowed for length assessment irrespective of angle of orientation. Cilia length was 
also measured in the same cells using x-y only projections, and measurements were 
compared for five cells. No observable difference in cilia length measurements were 
detected, and thus subsequent lengths were measured from x-y projections.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Missense mutations in the encoded enzymatic domain of INPP5E, (inositol polyphate-5-
phosphatase E) in patients linked to the JBTS1 locus. (a) Top: axial brain MRIs showing 
molar tooth sign (red circle) from one affected from each linked family, representing four 
different countries of origin. Bottom: midline sagittal MRIs showing horizontally-oriented 
superior cerebellar peduncle (red arrow), not evident in control. Sequence chromatograms 
from one affected from each family, showing the nucleotide change (red arrow), with 
corresponding amino acid substitution listed below. Families MTI-007 and MTI-134 shared 
a common haplotype at the JBTS1 locus, as did COR-10 and COR-21, and they share 
common mutations. MTI-007 and MTI-134 have a compound homozygous mutation with a 
double R512W; R515W. (b) Predicted protein domains of INPP5E indicated by color. Each 
of the identified missense mutations (arrows) occurs in a basic residue within the catalytic 
domain and alters charge. (c) Evolutionary conservation of mutated amino acids.
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Impaired 5-phosphatase activity and altered ratio of PtdIns(4,5)P2 to PtdIns(4)P associated 
with JBTS1 INPP5E mutations. (a) Summary of PtdIns metabolism. P = phosphate. A block 
in INPP5E function is predicted to increase the PtdIns(4,5)P2:PtdIns(4)P ratio. (b-c) More 
severe reduction in 5-phosphatase activity of mutant INPP5E against PtdIns(3,4,5)P3 than 
PtdIns(4,5)P2 substrates. Note that activity was largely retained against PtdIns(4,5)2 for 
some mutations (mutants R435Q, R512W/R515W and K580E are severely defective, 
whereas R378C and R563H are only slightly diminished). D477N is known 
phosphatasedead, compared with each of the patient mutations. (N = 3 for each sample) (d) 
Elevated ratio of PtdIns(4,5)P2 to PtdIns(4)P in patient primary fibroblast lines MTI-610-
V-2 and V-1, compared with control fibroblast. * represent p < 0.05 ANOVA two way 
corrected for multiple comparisons.
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Ciliary axonemal localization of INPP5E and enhanced ciliary lability in INPP5E mutant 
cell line. (a) RPE-hTERT ciliated cells stained for INPP5E and cilia markers. INPP5E (red, 
arrow) localized adjacent to pericentrin-positive (green, arrowhead) pericentriolar matrix. 
(b) Colocalization of INPP5E (red, arrow) with ciliary axonemal acetylated tubulin (green). 
(c-f) show INPP5E (red) staining in GFP-CETN2 transgenic mouse (green pair of centrioles, 
arrowheads). (c) P10 kidney collecting tubule shows INPP5E-positive red cilia projecting 
into the renal tubule lumen (inner dashes), limits of tubule indicated by outer dashes. (d) P5 
cerebellar internal granule layer with INPP5E (red, arrows) ciliary axoneme adjacent to the 
centrioles. (e) P10 retina, where GFP-CETN2 labels the basal body and connecting cilium 
(CC, green, arrowhead). INPP5E exclusively labels photoreceptor cells (red, arrow) (f) 
High-power view of (e) showing INPP5E staining (red, arrow) in the inner segment (IS), 
just adjacent to and above basal bodies and CC( arrowheads). Blue = Hoechst. Scale bar 5 
um (a-b,d), 25 um (c), 50 um (e), 10 um (f).
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(a) Lability of cilia in patient primary fibroblasts with mutant INPP5E. Prior to serum 
stimulation, serum-starved control and patient fibroblasts displayed comparable percentage 
of ciliated cells. By 4 hr after serum stimulation, the ciliated cells dropped to 43% in patient 
fibroblast as compared to 73% in control (* = p < 0.01, N =3, total cells counted >250 for 
each condition). By 8 hr or 24 hr after stimulation, ciliated cells were again comparable 
between patient and control samples. (b-e) Scanning electron micrographs of control vs. 
patient primary fibroblast with mutant INPP5E. Prior to serum stimulation, ciliary axonemal 
length is comparable, although slightly shorter in patient sample. By 4 hr after stimulation, 
axonemal length is shorter in patient sample. Scale bar indicated in um.
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